CMC1抗体—艾普蒂

CMC1 antibody, a cardiac-specific autoantibody, has gained attention in cardiovascular research due to its association with autoimmune-mediated heart diseases. Initially identified in patients with dilated cardiomyopathy (DCM), CMC1 targets intracellular cardiac proteins, potentially contributing to myocardial damage through immune-mediated mechanisms. Its presence correlates with cardiac dysfunction and adverse clinical outcomes, suggesting a role in disease progression. Studies propose that molecular mimicry triggered by viral infections or genetic predisposition may initiate autoantibody production. CMC1 is detected via immunoassays like ELISA or indirect immunofluorescence, often alongside other cardiac autoantibodies. While its exact antigenic target remains under investigation, it is hypothesized to interact with sarcomeric or mitochondrial proteins, disrupting cellular homeostasis. Clinically, CMC1 serves as a potential biomarker for stratifying DCM patients and guiding immunomodulatory therapies. However, its pathogenic mechanisms and diagnostic utility require further validation in larger cohorts. Current research explores its interplay with inflammatory pathways and potential as a therapeutic target in autoimmune cardiomyopathies.